Prasugrel

Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

Product Specifications

CAS Number

[150322-43-3]

Product Name Alternative

PCR 4099

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

P2Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/prasugrel.html

Concentration

10mM

Purity

99.85

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC1=CC=CC=C1C(C(C2CC2)=O)N3CCC4=C(C3)C=C(S4)OC(C)=O

Molecular Formula

C20H20FNO3S

Molecular Weight

373.45

Precautions

H315, H319, H320

References & Citations

[1]Wijeyeratne YD, et al. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011 Oct;72 (4) :647-57.|[2]Sugidachi A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007 Jul;5 (7) :1545-51.